Precision BioSciences, Inc. (NASDAQ:DTIL) Shares Sold by Tejara Capital Ltd

Tejara Capital Ltd lessened its stake in Precision BioSciences, Inc. (NASDAQ:DTIL) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,185 shares of the company’s stock after selling 3,173 shares during the quarter. Tejara Capital Ltd’s holdings in Precision BioSciences were worth $81,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Janus Henderson Group PLC raised its stake in shares of Precision BioSciences by 10.9% in the 3rd quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after acquiring an additional 68,943 shares during the period. Geode Capital Management LLC raised its stake in shares of Precision BioSciences by 40.7% in the 3rd quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock valued at $591,000 after acquiring an additional 19,088 shares during the period. Moloney Securities Asset Management LLC raised its stake in shares of Precision BioSciences by 177.0% in the 4th quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after acquiring an additional 56,100 shares during the period. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Precision BioSciences in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Stock Up 0.2 %

NASDAQ DTIL opened at $5.05 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company’s 50 day simple moving average is $5.12 and its 200 day simple moving average is $6.83. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $15.97. The company has a market capitalization of $38.74 million, a P/E ratio of 84.18 and a beta of 1.59.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DTIL. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a report on Wednesday, February 19th.

Insider Activity

In related news, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the transaction, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at approximately $500,096.29. The trade was a 25.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total transaction of $49,274.73. Following the completion of the sale, the insider now directly owns 87,440 shares of the company’s stock, valued at $418,837.60. This represents a 10.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 8,734 shares of company stock worth $39,946 and have sold 47,279 shares worth $222,064. 4.00% of the stock is owned by company insiders.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.